Perspective Therapeutics, Inc. (NYSE:CATX) CFO Purchases $49,006.78 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt acquired 12,829 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was acquired at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the transaction, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. This represents a 35.66 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Perspective Therapeutics Stock Up 5.8 %

Shares of NYSE:CATX opened at $4.36 on Friday. Perspective Therapeutics, Inc. has a 1 year low of $2.28 and a 1 year high of $19.05. The stock’s fifty day moving average price is $10.60 and its 200-day moving average price is $12.27.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, analysts forecast that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the third quarter worth about $57,000. US Bancorp DE increased its position in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after buying an additional 3,866 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics in the second quarter worth about $117,000. Point72 DIFC Ltd purchased a new stake in Perspective Therapeutics in the second quarter worth about $118,000. Finally, Intech Investment Management LLC purchased a new stake in Perspective Therapeutics in the third quarter worth about $137,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Oppenheimer reduced their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Truist Financial assumed coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Wedbush reissued an “outperform” rating and issued a $11.00 target price (down previously from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. Finally, UBS Group assumed coverage on Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics has an average rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.